A Clinical Study of DEB-TACE Combined With Surufatinib and Camrelizumab in the Treatment of Inoperable or Metastatic ICC

Summary

At present, for advanced Intrahepatic Cholangiocarcinoma（ICC）, the effect of single treatment is not good.So far, superselective drug-eluting bead transarterial chemoembolization（DEB-TACE） is a good method for the treatment of local lesions in advanced ICC.Studies have shown that the combination of sovantinib and immunotherapy has also shown encouraging results, and patients are well tolerated.Therefore, we designed DEB-TACE combined with Surufatinib and Camrelizumab for the exploratory study of inoperable or metastatic ICC, in order to provide a safe, effective and tolerable option for patients with ICC, prolong their survival time and improve their quality of life.

Timeline

Start

2022-02-01

Primary completion

2024-06-30

Completion

2025-01-31

Publications

• Guo B, Fan Y, Li D, Xia F, Luo C, Zhu J, Wu Y, Zhu Z, Xiang S, Liu E, Zhang W. Locoregional gemcitabine plus surufatinib and camrelizumab in FGFR2-non-altered intrahepatic cholangiocarcinoma. Cell Rep Med. 2025 Dec 16;6(12):102482. doi: 10.1016/j.xcrm.2025.102482. Epub 2025 Dec 4.

Drugs

Indications